logo
Plus   Neg
Share
Email

Alnylam Pharmaceuticals Inc. Q3 adjusted earnings Beat Estimates

Below are the earnings highlights for Alnylam Pharmaceuticals Inc. (ALNY):

-Earnings: -$253.29 million in Q3 vs. -$208.54 million in the same period last year.
-EPS: -$2.18 in Q3 vs. -$1.92 in the same period last year.
-Excluding items, Alnylam Pharmaceuticals Inc. reported adjusted earnings of -$183.60 million or -$1.58 per share for the period.
-Analysts projected -$1.66 per share
-Revenue: $125.85 million in Q3 vs. $70.06 million in the same period last year.

-Guidance:
Full year revenue guidance: $295 - $310 Mln

For comments and feedback contact: editorial@rttnews.com

Follow RTT